Swain J, Preeti , Mohanty C, Bajoria A, Patnaik S, Ward Gahlawat A
Discov Oncol. 2025; 16(1):275.
PMID: 40053174
PMC: 11889322.
DOI: 10.1007/s12672-025-01949-x.
Akbariani M, Omidi M, Shahabi Z, Haghi-Aminjan H, Shadboorestan A
Cancer Cell Int. 2025; 25(1):27.
PMID: 39875988
PMC: 11773746.
DOI: 10.1186/s12935-024-03622-9.
Grunfeld J, Moller P, Vogel U, Jensen S, Kofoed-Sorensen V, Andersen M
Toxics. 2024; 12(11).
PMID: 39591003
PMC: 11598809.
DOI: 10.3390/toxics12110825.
Pimentel G, Roder T, Bar C, Christensen S, Sattari Z, Kalbermatter C
Microbiol Spectr. 2024; :e0039324.
PMID: 39472005
PMC: 11619593.
DOI: 10.1128/spectrum.00393-24.
Olafsen N, Das S, Gorrini C, Matthews J
Front Oncol. 2024; 14:1466658.
PMID: 39450255
PMC: 11499230.
DOI: 10.3389/fonc.2024.1466658.
Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor.
Dexheimer T, Coussens N, Silvers T, Jones E, Chen L, Fang J
SLAS Discov. 2024; 29(7):100186.
PMID: 39362362
PMC: 11562894.
DOI: 10.1016/j.slasd.2024.100186.
The Aryl Hydrocarbon Receptor and Its Crosstalk: A Chemopreventive Target of Naturally Occurring and Modified Phytochemicals.
Szaefer H, Licznerska B, Baer-Dubowska W
Molecules. 2024; 29(18).
PMID: 39339278
PMC: 11433792.
DOI: 10.3390/molecules29184283.
Aryl hydrocarbon receptor dynamics in esophageal squamous cell carcinoma: From immune modulation to therapeutic opportunities.
Rahmati M, Moghtaderi H, Mohammadi S, Al-Harrasi A
World J Exp Med. 2024; 14(3):96269.
PMID: 39312702
PMC: 11372732.
DOI: 10.5493/wjem.v14.i3.96269.
High Expression of AhR and Environmental Pollution as AhR-Linked Ligands Impact on Oncogenic Signaling Pathways in Western Patients with Gastric Cancer-A Pilot Study.
Perrot-Applanat M, Pimpie C, Vacher S, Pocard M, Baud V
Biomedicines. 2024; 12(8).
PMID: 39200369
PMC: 11351739.
DOI: 10.3390/biomedicines12081905.
Predicting phase-I metabolism of piceatannol: an in silico study.
Rajan R, Engels M, Ramanathan M
In Silico Pharmacol. 2024; 12(1):52.
PMID: 38854674
PMC: 11153392.
DOI: 10.1007/s40203-024-00228-x.
Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types.
Kim D, Lee C, Han Y, Park S, Han H, Na K
Front Immunol. 2024; 15:1330228.
PMID: 38680496
PMC: 11045933.
DOI: 10.3389/fimmu.2024.1330228.
Association of decreased estimated glomerular filtration rate with lung cancer risk in the Korean population.
Shin S, Kim M, Oh C, Chun H, Ha E, Lee H
Epidemiol Health. 2024; 46:e2024041.
PMID: 38549355
PMC: 11369561.
DOI: 10.4178/epih.e2024041.
Comprehensive mapping of the AOP-Wiki database: identifying biological and disease gaps.
Jaylet T, Coustillet T, Smith N, Viviani B, Lindeman B, Vergauwen L
Front Toxicol. 2024; 6:1285768.
PMID: 38523647
PMC: 10958381.
DOI: 10.3389/ftox.2024.1285768.
Targeting aryl hydrocarbon receptor to prevent cancer in barrier organs.
Congues F, Wang P, Lee J, Lin D, Shahid A, Xie J
Biochem Pharmacol. 2024; 223:116156.
PMID: 38518996
PMC: 11144369.
DOI: 10.1016/j.bcp.2024.116156.
Supplement Use and Increased Risks of Cancer: Unveiling the Other Side of the Coin.
Jabbari P, Yazdanpanah O, Benjamin D, Kalebasty A
Cancers (Basel). 2024; 16(5).
PMID: 38473246
PMC: 10930792.
DOI: 10.3390/cancers16050880.
AHR signaling pathway mediates mitochondrial oxidative phosphorylation which leads to cytarabine resistance.
Jia Y, Li X, Chen L, Li L, Zhang S, Huang W
Acta Biochim Biophys Sin (Shanghai). 2024; 56(4):597-606.
PMID: 38404179
PMC: 11090854.
DOI: 10.3724/abbs.2024022.
Boron Compounds Mitigate 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Induced Toxicity in Human Peripheral Blood Mononuclear Cells.
Arslan M, Baba C, Tozlu O
Toxics. 2024; 12(2).
PMID: 38393193
PMC: 10891549.
DOI: 10.3390/toxics12020098.
The Aryl Hydrocarbon Receptor: Impact on the Tumor Immune Microenvironment and Modulation as a Potential Therapy.
Griffith B, Frankel T
Cancers (Basel). 2024; 16(3).
PMID: 38339226
PMC: 10854841.
DOI: 10.3390/cancers16030472.
Aryl hydrocarbon receptor is a tumor promoter in -amplified neuroblastoma cells through suppression of differentiation.
Chaudhry K, Jacobi J, Gillard B, Karasik E, Martin J, da Silva Fernandes T
iScience. 2023; 26(11):108303.
PMID: 38026169
PMC: 10654598.
DOI: 10.1016/j.isci.2023.108303.
Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.
Kober C, Roewe J, Schmees N, Roese L, Roehn U, Bader B
J Immunother Cancer. 2023; 11(11).
PMID: 37963637
PMC: 10649913.
DOI: 10.1136/jitc-2023-007495.